Detection of Recurrent Cytogenetic Abnormalities in Acute Lymphoblastic and Myeloid Leukemias Using Fluorescence In Situ Hybridization
Cytogenetic identification of clonal abnormalities present in leukemia is critical for accurate diagnosis of the disease and determination of specific therapeutic interventions for the patient. Fluorescence in situ hybridization (FISH) studies complement the diagnostic karyotype by providing a higher resolution of analysis with clarification of rearrangements observed by G-banding and identification of cryptic abnormalities not observed by the light microscope. This chapter will discuss FISH methodology as practiced in the cancer cytogenetic laboratory.
Key wordsCytogenetics Chromosomes Molecular cytogenetics Fluorescence in situ hybridization
The author would like to acknowledge the IU Cytogenetics Laboratory personnel and especially the FISH team members: Haki Choi, Ryan Stohler, Ryanne Berger, Lisa Wright, Matthew Sweckor, and Virginia Thurston. Thanks also to Shani Stiles for her talented clerical assistance.
- 1.Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Artheru DC et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336PubMedCrossRefGoogle Scholar
- 2.Nowell P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497Google Scholar
- 5.Brown J, Jawad M, Twigg SRF, Saracoglu K, Sauerbrey A, Thomas AD et al (2002) A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by multiplex fluorescence in situ hybridization telomere assay. Blood 99:2526–2531PubMedCrossRefGoogle Scholar
- 7.Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
- 8.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
- 13.Shaffer LG, Slovak ML, Campbell LJ (eds) (2009) ISCN (2009): an international system for human cytogenetic nomenclature. S. Karger, BaselGoogle Scholar
- 15.American College of Medical Genetics (2006) Standards and guidelines for clinical genetics laboratory. Section E. www.acmg.net/Pages/ACMG_Activities/Stds-2002/e.htm
- 16.Clinical Laboratory Standards Institute (2004) Fluorescence in situ hybridization (FISH) methods for medical genetics; Approved guidelines, vol MM7-A. 24. Wayne, PA, pp 1–46Google Scholar
- 17.Clinical Laboratory Improvement Amendments, 1988. http://www.access.gpo.gov/nara/cfr/waisidx_04/42cfr493_04.html
- 18.Proficiency Testing. http://www.cap.org/